(Reuters) -Hedge fund Starboard Value has taken a stake in Kenvue, the consumer products company that makes Band-Aid, ...

智通财经注意到，在击败最后的竞争对手 PAI Partners 后，Clayton Dubilier & Rice LLC 最终赢得了从赛诺菲 (SNY.US) 剥离出来的 Opella 消费者保健业务的拍卖。其Opella业务的估值约为160亿欧元 ...

Recent health news includes a court ruling allowing Amgen's Eylea biosimilar launch, Starboard criticizing Kenvue's skin ...

Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...

Recent health news includes Amgen's launch of an Eylea biosimilar in the U.S., Slovakia's bird flu outbreak, and China's ...

Adds Kenvue comment. Kenvue (NYSE:KVUE) needs to focus on fixing its skin, health and beauty segments, Jeff Smith, founder ...

Starboard Value, the activist investor pushing for changes at Pfizer, unveiled its goals for another healthcare company — ...

An exclusive Q&A with David Lickstein, Global Head of Packaging Innovation, Sustainability, and Experience, at Kenvue ...

Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster ...

Kenvue has a formidable lineup of well-known consumer health brands, such as Aveeno, Tylenol, Band-Aid, Zirtec, Listerine, ...

Starboard Value于2024年10月21日对成立不久的保健品销售商Kenvue进行战略投资，携手拓展个人护理产品市场。